Most borrowers sign their education loan documents without fully grasping one clause that will quietly reshape their repayment for years: the moratorium period. It sounds like a grace period, and in ...

Darklake/Zyga and Houdini move STKE up the Solana stack into privacy execution, APIs, routing, and middleware monetization. Core staking and validation rewards remained resilient in SOL terms, ...

The Securities and Exchange Commission proposed amendments that would give public companies the option to file reports semiannually, rather than on a quarterly basis as required by federal securities ...

The Securities and Exchange Commission announced on Tuesday it is moving forward with winding down how often public companies report earnings. The agency proposed its widely anticipated rule that ...

The Food and Drug Administration on April 30 proposed excluding Novo Nordisk and Eli Lilly's weight-loss drugs from a key compounding list, potentially limiting large-scale production by outsourcing ...

FDA proposes excluding blockbuster weight-loss drugs from 503B compounding list Move could limit bulk production by outsourcing facilities Novo and Lilly support FDA stance If finalized, the move ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

The FDA has clarified its policies regarding GLP-1s, stating that pharmacies must stop compounding GLP-1 drugs once branded versions are removed from the agency’s shortage list, signaling a narrower ...

Weight-loss company Noom has acquired 503A pharmacy Tailor Made Compounding, which Noom said will allow it to expand its behavior change programs and move beyond weight health. Tailor Made provides ...

Learn about compound interest. We will look at how to determine the final value, initial value, interest rate and years needed. We will investigate problems compounded continuously, daily, weekly, ...

Though it’s hard to say exactly what the future holds for mass GLP-1 compounding, the pressure is mounting from multiple angles in the U.S. as drugmakers and the FDA alike seek to crack down on the ...

The FDA is taking no prisoners as it continues its efforts to combat widespread GLP-1 drug compounding. In its latest offensive, the agency has unleashed a fresh set of 30 warning letters targeting ...